Type:

Lower dose EURneffy® nasal adrenaline spray approved by MHRA for younger children 30th June 2026

The Medicines and Healthcare products Regulatory Agency (MHRA) has approved a lower-dose version of the adrenaline nasal spray, EURneffy®, for the emergency treatment of serious allergic reactions (anaphylaxis) in children aged four years and over. This adrenaline device option is

Read more
NICE publishes updated anaphylaxis guidelines on assessment and referral after emergency treatment 18th June 2026

The National Institute for Health and Care Excellence (NICE) has published updated guidance on the assessment and referral of people following emergency treatment for anaphylaxis. This new guideline replaces NICE guideline CG134 (December 2011).  The update aims to improve the

Read more
Critical delays in use of AAIs in children, call to action  18th May 2026

New research from the University of Bristol and Bristol Royal Hospital for Children has highlighted critical delays in the use of adrenaline auto-injectors (AAIs) in children experiencing fatal food-induced anaphylaxis, prompting calls for urgent improvements in awareness, preparedness and guidance.   The findings, presented on

Read more
Why allergy awareness matters in healthcare 9th March 2026

Allergies can impact almost every aspect of daily life — from school and travel to attending a hospital appointment. That is why Anaphylaxis UK advocates for a safer, allergy-aware approach across all environments. In healthcare settings, it may be assumed

Read more
Allergy misinformation on social media 10th February 2026

A recent study published in The Journal of Allergy and Clinical Immunology: In Practice looked at popular allergy-related posts on TikTok, Instagram, Facebook and X to see what kind of misinformation is being shared and how people respond to it.  The researchers found that misleading content was very

Read more
Research opportunity: eating disorder risk in adults with and without food allergies 27th January 2026

A Trainee Clinical Psychologist at the University of Surrey is conducting a research study exploring the likelihood of eating disorders in adults with food allergy compared to adults without food allergy. While previous research suggests that children with food allergies

Read more
Palforzia® peanut oral immunotherapy – update  27th January 2026

You may have seen recent reports that Palforzia®, a licensed peanut oral immunotherapy treatment, has been discontinued. We can confirm that this is correct and outline below what this means for people living with peanut allergy.  The manufacturer of Palforzia®, Stallergenes Greer, has confirmed that

Read more
Research opportunity for adults living with food allergy 26th January 2026

Aston University, Birmingham, is inviting adults with a diagnosed food allergy to take part in a research study exploring how people cope with food allergies and how this affects everyday life. In particular, the study looks at whether feeling more

Read more
Research opportunity for UK Healthcare Professionals managing patients with food allergies 22nd January 2026

Kings College London are inviting Healthcare Professionals to complete a short survey about Milk Oral Immunotherapy (OIT). The research is concerned with mapping current milk OIT practice within the UK, and evaluating healthcare professionals attitudes, knowledge, training needs, and perceived

Read more